<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In the present study, we investigated <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced changes of <z:chebi fb="0" ids="18405">pyridoxal 5'-phosphate</z:chebi> synthesizing enzyme and degrading enzyme and neuroprotective effects and roles of <z:chebi fb="0" ids="18405">pyridoxal 5'-phosphate</z:chebi> against ischemic damage in the gerbil hippocampal CA1 region </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="18405">Pyridoxal 5'-phosphate</z:chebi> oxidase and <z:chebi fb="0" ids="18405">pyridoxal phosphate</z:chebi> phosphatase immunoreactivities were changed in neurons up to 2 days after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, while 4 days after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> their immunoreactivities were expressed in astrocytes </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="18405">Pyridoxal 5'-phosphate</z:chebi> oxidase immunoreactivity and its protein level were highest 12 h after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, while those in <z:chebi fb="0" ids="18405">pyridoxal phosphate</z:chebi> phosphatase were highest 2 days after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Total activities of these enzymes were changed after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, but specific activities of the enzymes were not altered </plain></SENT>
<SENT sid="4" pm="."><plain>Treatment with <z:chebi fb="0" ids="18405">pyridoxal 5'-phosphate</z:chebi> into brains (4 microg/5 microl, i.c.v.) at 30 min before <z:e sem="disease" ids="C0022118" disease_type="Disease or Syndrome" abbrv="">transient ischemia</z:e> protected about 80% of CA1 pyramidal cells 4 days after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> and induced elevation of glutamic acid decarboxylase 67 immunoreactivity in the CA1 region </plain></SENT>
<SENT sid="5" pm="."><plain>However, <z:chebi fb="0" ids="18405">pyridoxal 5'-phosphate</z:chebi> treatment into ischemic brains decreased <z:chebi fb="3" ids="16865">GABA</z:chebi> transaminase immunoreactivity in the CA1 region after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>These results indicate that <z:chebi fb="0" ids="18405">pyridoxal 5'-phosphate</z:chebi> may be associated with the inhibitory discharge of <z:chebi fb="3" ids="16865">GABA</z:chebi> in the hippocampal CA1 neurons, and the increased level of <z:chebi fb="3" ids="16865">GABA</z:chebi> may protect hippocampal CA1 pyramidal cells from ischemic damage </plain></SENT>
</text></document>